CLINICAL_TRIALS
trial_result
· 2015-01-29
Clinical Trial Update: Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease [Phase 2]
Summary
A Phase 2 study evaluating INS37217 inhalation solution for mild to moderate cystic fibrosis lung disease has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED